Neuronetics announces New York State Medicaid to begin covering TMS services

Neuronetics (STIM) announced that New York State Medicaid will begin covering Transcranial Magnetic Simulation, TMS, services for adults diagnosed with major depressive disorder, MDD. The coverage will take effect October 1, 2025, for fee-for-service Medicaid members, and November 1, 2025, for those enrolled in Medicaid Managed Care Plans. “This decision by New York State Medicaid reflects the growing recognition of TMS as an evidence-based, life-changing treatment for patients with depression,” said Keith Sullivan, President and CEO of Neuronetics, Inc. “We commend the state for making TMS more accessible to patients who need it most, and we remain committed to working alongside providers and policymakers to expand access nationwide.”